Markers and metabolites related to inflammation in bronchiectasis with airflow limitation vs. Chronic obstructive pulmonary disease

Jee Youn Oh, Adnan Khan, Young Seok Lee, Kyung-Hoon Min, Gyu Young Hur, Sung Yong Lee, Kyung Ho Kang, Jae Kwan Kim, Jae Jeong Shim, Youngja H. Park

Research output: Contribution to journalArticle

Abstract

Chronic obstructive pulmonary disease (COPD) is a systemic progressive inflammatory disease resulting from an abnormal inflammatory response to noxious stimuli. Bronchiectasis is also a chronic inflammatory condition, usually caused by repetitive infections. However, it is not clear whether the inflammatory signaling pathways involved are the same in both diseases. Therefore, we here compared the markers and metabolites related to inflammation in COPD and in bronchiectasis to elucidate the pathological mechanisms. We compared markers and metabolites in patients with COPD and in those with bronchiectasis with airflow limitation. The levels of the following inflammatory biomarkers were assessed: erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), interleukin (IL)-6, and club cell secretory protein (CC)-16. Additionally, high-resolution metabolomic evaluation was conducted to evaluate the differentially expressed metabolic signature of the two diseases. The ESR and CRP levels were significantly higher, and the levels of CC-16 and IL-6 tended to be higher, among patients with bronchiectasis than among those with COPD. In the metabolomics analysis, serum metabolites of biliverdin IX alpha (m/z: 565.24 [M+H-H2O]+) and L-carnitine (m/z: 184.09 [M+Na]+) were significantly upregulated in sera of bronchiectasis patients. In sera of COPD patients, the levels of nicotine (m/z: 163.12 [M+H]+) and N-acetyl serotonin (m/z: 201.102 [M+H-H2O]+) were significantly higher. Patients with bronchiectasis with airflow limitation had higher levels of inflammatory biomarkers (ESR and CRP) and markers indicating compensation for inflammatory damage (biliverdin IX alpha and L-carnitine), than did patients with COPD. Further treatments modulating the inflammatory process may be useful in patients with bronchiectasis.

Original languageEnglish
Pages (from-to)2925-2931
Number of pages7
JournalBiomedical Research (India)
Volume29
Issue number14
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Pulmonary diseases
Bronchiectasis
Metabolites
Chronic Obstructive Pulmonary Disease
Inflammation
Sedimentation
Blood Sedimentation
Biliverdine
C-Reactive Protein
Carnitine
Biomarkers
Metabolomics
Interleukin-6
Serum
Nicotine
Serotonin
Infection
Proteins

Keywords

  • Biomarkers
  • Bronchiectasis
  • Chronic obstructive pulmonary disorder
  • Club cell secretory protein
  • Inflammation
  • Metabolomics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Markers and metabolites related to inflammation in bronchiectasis with airflow limitation vs. Chronic obstructive pulmonary disease. / Oh, Jee Youn; Khan, Adnan; Lee, Young Seok; Min, Kyung-Hoon; Hur, Gyu Young; Lee, Sung Yong; Kang, Kyung Ho; Kim, Jae Kwan; Shim, Jae Jeong; Park, Youngja H.

In: Biomedical Research (India), Vol. 29, No. 14, 01.01.2018, p. 2925-2931.

Research output: Contribution to journalArticle

@article{8e0eeb6dee614c808da25f7f820f7734,
title = "Markers and metabolites related to inflammation in bronchiectasis with airflow limitation vs. Chronic obstructive pulmonary disease",
abstract = "Chronic obstructive pulmonary disease (COPD) is a systemic progressive inflammatory disease resulting from an abnormal inflammatory response to noxious stimuli. Bronchiectasis is also a chronic inflammatory condition, usually caused by repetitive infections. However, it is not clear whether the inflammatory signaling pathways involved are the same in both diseases. Therefore, we here compared the markers and metabolites related to inflammation in COPD and in bronchiectasis to elucidate the pathological mechanisms. We compared markers and metabolites in patients with COPD and in those with bronchiectasis with airflow limitation. The levels of the following inflammatory biomarkers were assessed: erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), interleukin (IL)-6, and club cell secretory protein (CC)-16. Additionally, high-resolution metabolomic evaluation was conducted to evaluate the differentially expressed metabolic signature of the two diseases. The ESR and CRP levels were significantly higher, and the levels of CC-16 and IL-6 tended to be higher, among patients with bronchiectasis than among those with COPD. In the metabolomics analysis, serum metabolites of biliverdin IX alpha (m/z: 565.24 [M+H-H2O]+) and L-carnitine (m/z: 184.09 [M+Na]+) were significantly upregulated in sera of bronchiectasis patients. In sera of COPD patients, the levels of nicotine (m/z: 163.12 [M+H]+) and N-acetyl serotonin (m/z: 201.102 [M+H-H2O]+) were significantly higher. Patients with bronchiectasis with airflow limitation had higher levels of inflammatory biomarkers (ESR and CRP) and markers indicating compensation for inflammatory damage (biliverdin IX alpha and L-carnitine), than did patients with COPD. Further treatments modulating the inflammatory process may be useful in patients with bronchiectasis.",
keywords = "Biomarkers, Bronchiectasis, Chronic obstructive pulmonary disorder, Club cell secretory protein, Inflammation, Metabolomics",
author = "Oh, {Jee Youn} and Adnan Khan and Lee, {Young Seok} and Kyung-Hoon Min and Hur, {Gyu Young} and Lee, {Sung Yong} and Kang, {Kyung Ho} and Kim, {Jae Kwan} and Shim, {Jae Jeong} and Park, {Youngja H.}",
year = "2018",
month = "1",
day = "1",
doi = "10.4066/biomedicalresearch.29-18-785",
language = "English",
volume = "29",
pages = "2925--2931",
journal = "Biomedical Research",
issn = "0970-938X",
publisher = "Scientific Publishers of India",
number = "14",

}

TY - JOUR

T1 - Markers and metabolites related to inflammation in bronchiectasis with airflow limitation vs. Chronic obstructive pulmonary disease

AU - Oh, Jee Youn

AU - Khan, Adnan

AU - Lee, Young Seok

AU - Min, Kyung-Hoon

AU - Hur, Gyu Young

AU - Lee, Sung Yong

AU - Kang, Kyung Ho

AU - Kim, Jae Kwan

AU - Shim, Jae Jeong

AU - Park, Youngja H.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Chronic obstructive pulmonary disease (COPD) is a systemic progressive inflammatory disease resulting from an abnormal inflammatory response to noxious stimuli. Bronchiectasis is also a chronic inflammatory condition, usually caused by repetitive infections. However, it is not clear whether the inflammatory signaling pathways involved are the same in both diseases. Therefore, we here compared the markers and metabolites related to inflammation in COPD and in bronchiectasis to elucidate the pathological mechanisms. We compared markers and metabolites in patients with COPD and in those with bronchiectasis with airflow limitation. The levels of the following inflammatory biomarkers were assessed: erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), interleukin (IL)-6, and club cell secretory protein (CC)-16. Additionally, high-resolution metabolomic evaluation was conducted to evaluate the differentially expressed metabolic signature of the two diseases. The ESR and CRP levels were significantly higher, and the levels of CC-16 and IL-6 tended to be higher, among patients with bronchiectasis than among those with COPD. In the metabolomics analysis, serum metabolites of biliverdin IX alpha (m/z: 565.24 [M+H-H2O]+) and L-carnitine (m/z: 184.09 [M+Na]+) were significantly upregulated in sera of bronchiectasis patients. In sera of COPD patients, the levels of nicotine (m/z: 163.12 [M+H]+) and N-acetyl serotonin (m/z: 201.102 [M+H-H2O]+) were significantly higher. Patients with bronchiectasis with airflow limitation had higher levels of inflammatory biomarkers (ESR and CRP) and markers indicating compensation for inflammatory damage (biliverdin IX alpha and L-carnitine), than did patients with COPD. Further treatments modulating the inflammatory process may be useful in patients with bronchiectasis.

AB - Chronic obstructive pulmonary disease (COPD) is a systemic progressive inflammatory disease resulting from an abnormal inflammatory response to noxious stimuli. Bronchiectasis is also a chronic inflammatory condition, usually caused by repetitive infections. However, it is not clear whether the inflammatory signaling pathways involved are the same in both diseases. Therefore, we here compared the markers and metabolites related to inflammation in COPD and in bronchiectasis to elucidate the pathological mechanisms. We compared markers and metabolites in patients with COPD and in those with bronchiectasis with airflow limitation. The levels of the following inflammatory biomarkers were assessed: erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), interleukin (IL)-6, and club cell secretory protein (CC)-16. Additionally, high-resolution metabolomic evaluation was conducted to evaluate the differentially expressed metabolic signature of the two diseases. The ESR and CRP levels were significantly higher, and the levels of CC-16 and IL-6 tended to be higher, among patients with bronchiectasis than among those with COPD. In the metabolomics analysis, serum metabolites of biliverdin IX alpha (m/z: 565.24 [M+H-H2O]+) and L-carnitine (m/z: 184.09 [M+Na]+) were significantly upregulated in sera of bronchiectasis patients. In sera of COPD patients, the levels of nicotine (m/z: 163.12 [M+H]+) and N-acetyl serotonin (m/z: 201.102 [M+H-H2O]+) were significantly higher. Patients with bronchiectasis with airflow limitation had higher levels of inflammatory biomarkers (ESR and CRP) and markers indicating compensation for inflammatory damage (biliverdin IX alpha and L-carnitine), than did patients with COPD. Further treatments modulating the inflammatory process may be useful in patients with bronchiectasis.

KW - Biomarkers

KW - Bronchiectasis

KW - Chronic obstructive pulmonary disorder

KW - Club cell secretory protein

KW - Inflammation

KW - Metabolomics

UR - http://www.scopus.com/inward/record.url?scp=85052750850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052750850&partnerID=8YFLogxK

U2 - 10.4066/biomedicalresearch.29-18-785

DO - 10.4066/biomedicalresearch.29-18-785

M3 - Article

VL - 29

SP - 2925

EP - 2931

JO - Biomedical Research

JF - Biomedical Research

SN - 0970-938X

IS - 14

ER -